Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CHD1Li 6.11 is a potent inhibitor of oncogenic CHD1L, acting on the cat-CHD1L recombinant protein (IC50: 3.3 μM). CHD1Li 6.11 is an orally active antitumour agent that significantly reduces the tumour volume of CRC xenografts generated from isolated quasi-mesenchymal cells (M phenotype) with enhanced tumourigenic properties. These cells have enhanced tumourigenic properties.
説明 | CHD1Li 6.11 is a potent inhibitor of oncogenic CHD1L, acting on the cat-CHD1L recombinant protein (IC50: 3.3 μM). CHD1Li 6.11 is an orally active antitumour agent that significantly reduces the tumour volume of CRC xenografts generated from isolated quasi-mesenchymal cells (M phenotype) with enhanced tumourigenic properties. These cells have enhanced tumourigenic properties. |
ターゲット&IC50 | Catalytic CHD1L:3.3 µM |
分子量 | 472.4 |
分子式 | C21H22BrN5OS |
CAS No. | 2716890-91-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (190.5 mM ), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CHD1Li 6.11 2716890-91-2 Others Inhibitor inhibitor inhibit